‘It’s us against the world’: And George Yancopoulos wants you to know they are beating the world — big time
George Yancopoulos doesn’t think very highly of the competition Regeneron $REGN faces in the frenzied scramble for a major share of the PD-1/L1 market.
During a fairly brief sit-down at JPMorgan, the Regeneron R&D chief ridiculed Pfizer’s choice for checkpoint partnering, said market leader Merck was now being forced to play catch-up on Regeneron’s first approved indication for their checkpoint Libtayo (cemiplimab) and slammed the use of PD-L1s in general — one of two targets used to release an immune system attack on cancer cells — as “medical malpractice.”
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.